Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide LAR for Lymphocele Prevention in Breast Cancer
NCT01356862Phase 2Completed
- Sponsor
- Alliance pour la Recherche en Cancérologie
- Start
- Sep 2010
- Primary completion
- Oct 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lymphocele comparing Pasireotide with Placebo (2 arms). Primary endpoint: Aspirations global volume of lymphoceles. Started Sep 2010; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
lymphocele
Beyond the preview
Go deeper on NCT01356862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01356862.